Stock analysts at Noble Financial raised their Q2 2026 earnings per share (EPS) estimates for AZZ in a research note issued ...

Stock analysts at Noble Financial issued their FY2024 earnings per share (EPS) estimates for Gyre Therapeutics in a research report issued to clients and investors on Tuesday, March 11th. Noble ...

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Cadrenal Therapeutics, Inc. (CVKD – Research ...

Barnes & Noble Education, Inc. announced its financial results for the third quarter of fiscal year 2025, showing a 2.1% increase in revenue to $466.3 million, primarily driven by a 21% year-over ...

Barnes & Noble Education's business is highly seasonal, with the major portion of sales and operating profit realized during ...

Barnes & Noble Education’s business is highly seasonal, with the major portion of sales and operating profit realized during the second and third fiscal quarters. Q3 and YTD FY2025 Financial ...